Gastrointestinal Disorders
Cure8 research brief
Why This Matters
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Who Should Pay Attention
Adults with IBD considering or taking thiopurines, anti-TNF drugs, newer biologics (vedolizumab, ustekinumab), JAK inhibitors, or S1P modulators; clinicians making treatment choices; researchers tracking long-term safety.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The review pooled and assessed 28 studies (randomized and observational) through June 2025. Thiopurines showed the most consistent links to certain cancers (lymphoma, non-melanoma skin cancer, and others).
Anti-TNF drugs alone did not show a clear overall cancer increase, but combining anti-TNF with thiopurines had the strongest lymphoma signal in available data.
Newer biologics (vedolizumab, ustekinumab) have not shown clear increased malignancy risk in the cohorts studied so far, but these findings are limited by small numbers of cancer events, heterogeneous patient histories, and short follow-up in many studies.
Janus kinase inhibitors and S1P modulators have limited IBD-specific long-term data; continued surveillance is needed. Treatment decisions should consider baseline cancer risk factors (age, smoking, prior malignancy or NMSC, EBV status) and cumulative immunosuppression rather than assuming equal risk across therapies.
Keep In Mind
The paper is a systematic review (abstract-level content provided). It did not perform a new pooled meta-analysis because of study heterogeneity; confidence is limited for newer therapies due to small event counts, observational designs, and limited follow-up.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationGastrointestinal Disorders
AuthorsGurleen Kaur, Rahul Jain, Palak Grover +3 more
InstitutionGovernment Medical College, Amritsar
Study typeReview
Indexed viaOpenAlex
Source typeResearch paper
PublishedJul 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's? - Medscape
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...